AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10375185 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation (leuploride and chlormadinone acetate) for 3 months preoperatively followed by radical prostatectomy and adjuvant endocrine therapy (leuploride only)
Number of subjects: 176
Study 10375185 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy followed by 3 months of androgen deprivation and subsequent adjuvant endocrine therapy
Number of subjects: 176
Study 10375185 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative androgen deprivation for stage C cancer patients
Number of subjects: 176
Study 9038462 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 1 ml.kg‐1 of 0.25% bupivacaine with 0.25 mg.kg‐1 of preservative‐free ketamine
Number of subjects: 60
Study 9038462 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 1 ml.kg‐1 of 0.25% bupivacaine with 0.5 mg.kg‐1 of ketamine
Number of subjects: 60
Study 9038462 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 1 ml.kg‐1 of 0.25% bupivacaine with 1 mg.kg‐1 of ketamine
Number of subjects: 60
Study 1442655 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg Ca as carbonate daily with meals)
Number of subjects: 109
Study 1442655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 109
Study 3900116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin 0.3 mg/kg bid
Number of subjects: 60
Study 3900116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin 0.7 mg/kg bid
Number of subjects: 60
Study 3900116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31842841 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (group SC)
Number of subjects: 42
Study 31842841 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium-sugammadex (group RS)
Number of subjects: 42
Study 30208380 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 221
Study 30208380 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 221
Study 27129472 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (standardized weekly group yoga class with home practice)
Number of subjects: 120
Study 27129472 — intervention group
Group type: COMPARATOR
Intervention: Education intervention (self-care book)
Number of subjects: 120
Study 25371053 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNF (adalimumab, Humira®, Abbott) 40 mg s.c.
Number of subjects: 30
Study 25371053 — intervention group
Group type: EXPERIMENTAL
Intervention: oral methylprednisolone 20 mg/day during 7 days
Number of subjects: 30
Study 25371053 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 30
Study 22951084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum tolerable daily dose of 1800 mg)
Number of subjects: 62
Study 22951084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19486025 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 400 IU twice daily (D group)
Number of subjects: 40
Study 19486025 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D(3) oil 97333 IU every 4 months (4 M group)
Number of subjects: 40
Study 19486025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17998780 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-leukocyte gel (PLG)
Number of subjects: 40
Study 17998780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PLG)
Number of subjects: 40
Study 16185403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of L-arginine (2% of total caloric value)
Number of subjects: 10
Study 16185403 — intervention group
Group type: COMPARATOR
Intervention: Compound 14 amino acid injection (2% of total caloric value)
Number of subjects: 10
Study 16185403 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 10
Study 12100090 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol administered 1 min after sumatriptan
Number of subjects: 24
Study 12100090 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol administered 30 min after sumatriptan
Number of subjects: 24
Study 12100090 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sumatriptan
Number of subjects: 24
Study 12100090 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sumatriptan and butorphanol
Number of subjects: 24
Study 10442961 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted injections of 5 ml mepivacaine 1% with epinephrine (MEPE)
Number of subjects: 106
Study 10442961 — intervention group
Group type: COMPARATOR
Intervention: Single injection of 80 mL MEPE 1%
Number of subjects: 106
Study 8551821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 129
Study 8551821 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glyceryl trinitrate
Number of subjects: 129
Study 2191595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 12
Study 2191595 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg qid
Number of subjects: 12
Study 2191595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ranitidine-matched) bid
Number of subjects: 12
Study 68285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass-media campaigns over a 2-year period in two communities
Number of subjects: 0
Study 68285 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counselling for a small subset of high-risk people
Number of subjects: 0
Study 68285 — intervention group
Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 0
Study 31782931 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30
Study 31782931 — intervention group
Group type: COMPARATOR
Intervention: Strength Training with Blood Flow Restriction (ST-BFR)
Number of subjects: 30
Study 30923776 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training intervention
Number of subjects: 50
Study 30923776 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 50
Study 28702807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-pause training (4-s unloaded rest between repetitions)
Number of subjects: 20
Study 28702807 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 20
Study 28702807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Rest-pause and Traditional)
Number of subjects: 20
Study 25560820 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day of olive extract and 1000 mg Ca
Number of subjects: 64
Study 25560820 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg Ca alone (placebo)
Number of subjects: 64
Study 23871127 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Psychotherapy and Illness Management
Number of subjects: 83
Study 23871127 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management Only
Number of subjects: 83
Study 23871127 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 83
Study 21336438 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immune-enhancing formula (DS group)
Number of subjects: 82
Study 21336438 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative intravenous fluids (DNS group)
Number of subjects: 82
Study 17978833 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast water therapy (CWT)
Number of subjects: 38
Study 17978833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 38
Study 17978833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (HWI)
Number of subjects: 38
Study 17978833 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 38
Study 15702819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (250/50 microg twice daily)
Number of subjects: 192
Study 15702819 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (250 microg twice daily)
Number of subjects: 192
Study 12934861 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated case management (ICM) approach with problem solving skills training and workplace accommodation
Number of subjects: 70
Study 12934861 — intervention group
Group type: COMPARATOR
Intervention: Control group (case managers who did not receive training)
Number of subjects: 70
Study 10376232 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of three sessions on AHCPR depression guidelines and case-finding instrument for depression
Number of subjects: 160
Study 10376232 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 160
Study 10376232 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention residents)
Number of subjects: 160
Study 8762735 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microgram/min GnRH
Number of subjects: 24
Study 8762735 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microgram/min GnRH
Number of subjects: 24
Study 8762735 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microgram/min GnRH
Number of subjects: 24
Study 8762735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microgram/min GnRH
Number of subjects: 24
Study 1757390 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% VO2max
Number of subjects: 6
Study 1757390 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% VO2max
Number of subjects: 6
Study 1757390 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% VO2max
Number of subjects: 6
Study 1757390 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% VO2max
Number of subjects: 6
Study 1757390 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% VO2max
Number of subjects: 6
Study 7201838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosaldon (1-hexyl-3,7-dimethylxanthine + nicotinic acid)
Number of subjects: 12
Study 7201838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29470249 — intervention group
Group type: EXPERIMENTAL
Intervention: elevated serum uric acid (eSUA)
Number of subjects: 101
Study 29470249 — intervention group
Group type: COMPARATOR
Intervention: non-elevated serum uric acid (non-eSUA)
Number of subjects: 101
Study 27521806 — intervention group
Group type: EXPERIMENTAL
Intervention: On the Move group exercise program
Number of subjects: 0
Study 27521806 — intervention group
Group type: COMPARATOR
Intervention: Standard group exercise program
Number of subjects: 0
Study 24107360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 3690
Study 22100357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2mg
Number of subjects: 30
Study 22100357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5mg
Number of subjects: 30
Study 22100357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 30
Study 22100357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (both doses)
Number of subjects: 30
Study 20690560 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a with ribavirin
Number of subjects: 443
Study 20690560 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2a with ribavirin
Number of subjects: 443
Study 20690560 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 443
Study 20690560 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2a
Number of subjects: 443
Study 20690560 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow response (detectable HCV RNA at week 12 and undetectable at week 24)
Number of subjects: 443
Study 18387159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 12.5 mg
Number of subjects: 120
Study 18387159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 25 mg
Number of subjects: 120
Study 18387159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 50 mg
Number of subjects: 120
Study 18387159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16311279 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 67
Study 16311279 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin 4%
Number of subjects: 67
Study 16311279 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 6%
Number of subjects: 67
Study 16311279 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 5%
Number of subjects: 67
Study 12904966 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 27
Study 12904966 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 27
Study 12904966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11035971 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III collagen deficiency in AAA patients
Number of subjects: 138
Study 11035971 — intervention group
Group type: COMPARATOR
Intervention: Normal type III collagen in family members
Number of subjects: 138
Study 11035971 — intervention group
Group type: COMPARATOR
Intervention: Screening for AAA in relatives
Number of subjects: 138
Study 8673778 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine
Number of subjects: 180
Study 8673778 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine with epinephrine
Number of subjects: 180
Study 8673778 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain 1% lidocaine with epinephrine
Number of subjects: 180
Study 8673778 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% diphenhydramine with epinephrine
Number of subjects: 180
Study 8673778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 180
Study 8673778 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine with epinephrine
Number of subjects: 180
Study 1666460 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin
Number of subjects: 456
Study 1666460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 456
Study 6145734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 0
Study 6145734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam with a narcotic
Number of subjects: 0
Study 31250832 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive users dataset
Number of subjects: 540
Study 31250832 — intervention group
Group type: COMPARATOR
Intervention: Control dataset
Number of subjects: 540
Study 31250832 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive users and depressive tweets datasets
Number of subjects: 540
Study 31250832 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive tweets dataset
Number of subjects: 540
Study 28954218 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (Detemir, Aspart, and their combination) as an add-on to metformin for 4 weeks
Number of subjects: 42
Study 26818362 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised information and emotional support (30 minutes) provided one day before surgery
Number of subjects: 253
Study 26818362 — intervention group
Group type: COMPARATOR
Intervention: Routine information as usual (control group)
Number of subjects: 253
Study 24602411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (up to 16 mg/24 h)
Number of subjects: 267
Study 24602411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 22724619 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interventions (n=459)
Number of subjects: 667
Study 22724619 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=208)
Number of subjects: 667
Study 20043182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy (NFC)
Number of subjects: 60
Study 20043182 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endothelin-1 (ET-1) measurement
Number of subjects: 60
Study 20043182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy (NFC) and plasma ET-1 correlation
Number of subjects: 60
Study 17437832 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization of the video screen during cystoscopy (Group 1)
Number of subjects: 100
Study 17437832 — intervention group
Group type: COMPARATOR
Intervention: No visualization of the video screen during cystoscopy (Group 2)
Number of subjects: 100
Study 16415516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonated Ringer's solution
Number of subjects: 20
Study 16415516 — intervention group
Group type: COMPARATOR
Intervention: Acetated Ringer's solution
Number of subjects: 20
Study 12578513 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite feedback presentations, performance improvement materials, comparative measures of performance of predefined quality indicators (intervention group)
Number of subjects: 36
Study 12578513 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 hospitals)
Number of subjects: 36
Study 10385715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid dilator (Savary)
Number of subjects: 251
Study 10385715 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilator (Microvasive)
Number of subjects: 251
Study 10385715 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilator (Bard)
Number of subjects: 251
Study 10385715 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe strictures
Number of subjects: 251
Study 10385715 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Rigid and Balloon)
Number of subjects: 251
Study 8734709 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin VK group
Number of subjects: 32
Study 8734709 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 32
Study 8734709 — intervention group
Group type: COMPARATOR
Intervention: Neither medication group
Number of subjects: 32
Study 2021446 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (n = 1,609)
Number of subjects: 3234
Study 2021446 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretic (n = 1,625)
Number of subjects: 3234
Study 7138230 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community ward
Number of subjects: 123
Study 7138230 — intervention group
Group type: COMPARATOR
Intervention: Medically oriented psychiatric ward
Number of subjects: 123
Study 30452739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch and behavioral counseling
Number of subjects: 525
Study 30153360 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bifrontal tDCS with concurrent CBT
Number of subjects: 14
Study 30153360 — intervention group
Group type: COMPARATOR
Intervention: Sham bifrontal tDCS with concurrent CBT
Number of subjects: 14
Study 30375894 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 60% of peak oxygen consumption
Number of subjects: 27
Study 30375894 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 90% of peak oxygen consumption
Number of subjects: 27
Study 30375894 — intervention group
Group type: COMPARATOR
Intervention: Comparison of moderate and severe COPD groups
Number of subjects: 27
Study 26549819 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 129
Study 26549819 — intervention group
Group type: COMPARATOR
Intervention: WGLL
Number of subjects: 129
Study 25016922 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC), 3 cycles of lower limb ischemic conditioning before allograft reperfusion.
Number of subjects: 60
Study 25016922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RIC).
Number of subjects: 60
Study 25016922 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC).
Number of subjects: 60
Study 21106282 — intervention group
Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 2% ropivacaine
Number of subjects: 40
Study 21106282 — intervention group
Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 1% ropivacaine
Number of subjects: 40
Study 21106282 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of 2.5% lidocaine and 2.5% prilocaine (EMLA)
Number of subjects: 40
Study 21106282 — intervention group
Group type: COMPARATOR
Intervention: liposomal placebo gel
Number of subjects: 40
Study 19843060 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (CLZ) alone
Number of subjects: 20
Study 19843060 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine-Risperidone (CLZ-RISP) combination
Number of subjects: 20
Study 17495570 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal DXA information (experimental group)
Number of subjects: 203
Study 17495570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personal DXA information)
Number of subjects: 203
Study 15973213 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radioguided parathyroidectomy (MIRP)
Number of subjects: 69
Study 15973213 — intervention group
Group type: COMPARATOR
Intervention: Bilateral exploration of the neck
Number of subjects: 69
Study 11940299 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during hemodialysis
Number of subjects: 20
Study 11940299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study 9775742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 7716838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin, bacille Calmette‐Guérin (BCG)‐RIVM or BCG‐Tice
Number of subjects: 52
Study 7716838 — intervention group
Group type: COMPARATOR
Intervention: Nonresponding patients
Number of subjects: 52
Study 2496989 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster injection of 0.1, 0.25 or 0.5 ml of diphtheria-tetanus vaccine
Number of subjects: 457
Study 2496989 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria-tetanus primary vaccinations over wider intervals
Number of subjects: 457
Study 197502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing services (treatment group)
Number of subjects: 110
Study 197502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nursing services)
Number of subjects: 110
Study 197502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110